Selected research
Industry Research
Recombinant Human Interleukin 2 Injection Industry Research Report 2026
Market perspective
The global Recombinant Human Interleukin 2 Injection market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Recombinant Human Interleukin 2 Injection is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Recombinant Human Interleukin 2 Injection is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Recombinant Human Interleukin 2 Injection is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Recombinant Human Interleukin 2 Injection include Beijing Yuance Pharmaceutical, Beijing SL Pharm, Shanghai Huaxin Biology Gaojishu, Shandong Quangang Pharmaceutical, Jiangsu Jinsili Pharmaceutical, Beijing Four Rings Biopharmaceutical and 3SBio, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Recombinant Human Interleukin 2 Injection market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Recombinant Human Interleukin 2 Injection Market by Company
Beijing Yuance Pharmaceutical
Beijing SL Pharm
Shanghai Huaxin Biology Gaojishu
Shandong Quangang Pharmaceutical
Jiangsu Jinsili Pharmaceutical
Beijing Four Rings Biopharmaceutical
3SBio
Recombinant Human Interleukin 2 Injection Segment by Type
50000 U
100000 U
200000 U
500000 U
1 Million U
Other
Recombinant Human Interleukin 2 Injection Segment by Application
Hospital
Pharmacy
Recombinant Human Interleukin 2 Injection Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Human Interleukin 2 Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Recombinant Human Interleukin 2 Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Human Interleukin 2 Injection.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Recombinant Human Interleukin 2 Injection manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Recombinant Human Interleukin 2 Injection by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Recombinant Human Interleukin 2 Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 50000 U
- 100000 U
- 200000 U
- 500000 U
- 1 Million U
- Other
Applications
- Hospital
- Pharmacy
Companies covered
- Beijing Yuance Pharmaceutical
- Beijing SL Pharm
- Shanghai Huaxin Biology Gaojishu
- Shandong Quangang Pharmaceutical
- Jiangsu Jinsili Pharmaceutical
- Beijing Four Rings Biopharmaceutical
- 3SBio
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Recombinant Human Interleukin 2 Injection Market Size (2021-2032)
- 2.2.2 Global Recombinant Human Interleukin 2 Injection Sales (2021-2032)
- 2.2.3 Global Recombinant Human Interleukin 2 Injection Market Average Price (2021-2032)
- 2.3 Recombinant Human Interleukin 2 Injection by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 50000 U
- 2.3.3 100000 U
- 2.3.4 200000 U
- 2.3.5 500000 U
- 2.3.6 1 Million U
- 2.3.7 Other
- 2.4 Recombinant Human Interleukin 2 Injection by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Pharmacy
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Recombinant Human Interleukin 2 Injection Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Recombinant Human Interleukin 2 Injection Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Recombinant Human Interleukin 2 Injection Revenue of Manufacturers (2021-2026)
- 3.4 Global Recombinant Human Interleukin 2 Injection Average Price by Manufacturers (2021-2026)
- 3.5 Global Recombinant Human Interleukin 2 Injection Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Recombinant Human Interleukin 2 Injection, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Recombinant Human Interleukin 2 Injection, Product Type & Application
- 3.8 Global Manufacturers of Recombinant Human Interleukin 2 Injection, Established Date
- 3.9 Global Recombinant Human Interleukin 2 Injection Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Beijing Yuance Pharmaceutical
- 4.1.1 Beijing Yuance Pharmaceutical Company Information
- 4.1.2 Beijing Yuance Pharmaceutical Business Overview
- 4.1.3 Beijing Yuance Pharmaceutical Recombinant Human Interleukin 2 Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Beijing Yuance Pharmaceutical Recombinant Human Interleukin 2 Injection Product Portfolio
- 4.1.5 Beijing Yuance Pharmaceutical Recent Developments
- 4.2 Beijing SL Pharm
- 4.2.1 Beijing SL Pharm Company Information
- 4.2.2 Beijing SL Pharm Business Overview
- 4.2.3 Beijing SL Pharm Recombinant Human Interleukin 2 Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Beijing SL Pharm Recombinant Human Interleukin 2 Injection Product Portfolio
- 4.2.5 Beijing SL Pharm Recent Developments
- 4.3 Shanghai Huaxin Biology Gaojishu
- 4.3.1 Shanghai Huaxin Biology Gaojishu Company Information
- 4.3.2 Shanghai Huaxin Biology Gaojishu Business Overview
- 4.3.3 Shanghai Huaxin Biology Gaojishu Recombinant Human Interleukin 2 Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Shanghai Huaxin Biology Gaojishu Recombinant Human Interleukin 2 Injection Product Portfolio
- 4.3.5 Shanghai Huaxin Biology Gaojishu Recent Developments
- 4.4 Shandong Quangang Pharmaceutical
- 4.4.1 Shandong Quangang Pharmaceutical Company Information
- 4.4.2 Shandong Quangang Pharmaceutical Business Overview
- 4.4.3 Shandong Quangang Pharmaceutical Recombinant Human Interleukin 2 Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Shandong Quangang Pharmaceutical Recombinant Human Interleukin 2 Injection Product Portfolio
- 4.4.5 Shandong Quangang Pharmaceutical Recent Developments
- 4.5 Jiangsu Jinsili Pharmaceutical
- 4.5.1 Jiangsu Jinsili Pharmaceutical Company Information
- 4.5.2 Jiangsu Jinsili Pharmaceutical Business Overview
- 4.5.3 Jiangsu Jinsili Pharmaceutical Recombinant Human Interleukin 2 Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Jiangsu Jinsili Pharmaceutical Recombinant Human Interleukin 2 Injection Product Portfolio
- 4.5.5 Jiangsu Jinsili Pharmaceutical Recent Developments
- 4.6 Beijing Four Rings Biopharmaceutical
- 4.6.1 Beijing Four Rings Biopharmaceutical Company Information
- 4.6.2 Beijing Four Rings Biopharmaceutical Business Overview
- 4.6.3 Beijing Four Rings Biopharmaceutical Recombinant Human Interleukin 2 Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Beijing Four Rings Biopharmaceutical Recombinant Human Interleukin 2 Injection Product Portfolio
- 4.6.5 Beijing Four Rings Biopharmaceutical Recent Developments
- 4.7 3SBio
- 4.7.1 3SBio Company Information
- 4.7.2 3SBio Business Overview
- 4.7.3 3SBio Recombinant Human Interleukin 2 Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 3SBio Recombinant Human Interleukin 2 Injection Product Portfolio
- 4.7.5 3SBio Recent Developments
5 Global Recombinant Human Interleukin 2 Injection Market Scenario by Region
- 5.1 Global Recombinant Human Interleukin 2 Injection Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Recombinant Human Interleukin 2 Injection Sales by Region: 2021-2032
- 5.2.1 Global Recombinant Human Interleukin 2 Injection Sales by Region: 2021-2026
- 5.2.2 Global Recombinant Human Interleukin 2 Injection Sales by Region: 2027-2032
- 5.3 Global Recombinant Human Interleukin 2 Injection Revenue by Region: 2021-2032
- 5.3.1 Global Recombinant Human Interleukin 2 Injection Revenue by Region: 2021-2026
- 5.3.2 Global Recombinant Human Interleukin 2 Injection Revenue by Region: 2027-2032
- 5.4 North America Recombinant Human Interleukin 2 Injection Market Facts & Figures by Country
- 5.4.1 North America Recombinant Human Interleukin 2 Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Recombinant Human Interleukin 2 Injection Sales by Country (2021-2032)
- 5.4.3 North America Recombinant Human Interleukin 2 Injection Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Recombinant Human Interleukin 2 Injection Market Facts & Figures by Country
- 5.5.1 Europe Recombinant Human Interleukin 2 Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Recombinant Human Interleukin 2 Injection Sales by Country (2021-2032)
- 5.5.3 Europe Recombinant Human Interleukin 2 Injection Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Recombinant Human Interleukin 2 Injection Market Facts & Figures by Country
- 5.6.1 Asia Pacific Recombinant Human Interleukin 2 Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Recombinant Human Interleukin 2 Injection Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Recombinant Human Interleukin 2 Injection Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Recombinant Human Interleukin 2 Injection Market Facts & Figures by Country
- 5.7.1 South America Recombinant Human Interleukin 2 Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Recombinant Human Interleukin 2 Injection Sales by Country (2021-2032)
- 5.7.3 South America Recombinant Human Interleukin 2 Injection Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa Recombinant Human Interleukin 2 Injection Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Recombinant Human Interleukin 2 Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Recombinant Human Interleukin 2 Injection Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Recombinant Human Interleukin 2 Injection Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Recombinant Human Interleukin 2 Injection Sales by Type (2021-2032)
- 6.1.1 Global Recombinant Human Interleukin 2 Injection Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Recombinant Human Interleukin 2 Injection Sales Market Share by Type (2021-2032)
- 6.2 Global Recombinant Human Interleukin 2 Injection Revenue by Type (2021-2032)
- 6.2.1 Global Recombinant Human Interleukin 2 Injection Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Recombinant Human Interleukin 2 Injection Revenue Market Share by Type (2021-2032)
- 6.3 Global Recombinant Human Interleukin 2 Injection Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Recombinant Human Interleukin 2 Injection Sales by Application (2021-2032)
- 7.1.1 Global Recombinant Human Interleukin 2 Injection Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Recombinant Human Interleukin 2 Injection Sales Market Share by Application (2021-2032)
- 7.2 Global Recombinant Human Interleukin 2 Injection Revenue by Application (2021-2032)
- 7.2.1 Global Recombinant Human Interleukin 2 Injection Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Recombinant Human Interleukin 2 Injection Revenue Market Share by Application (2021-2032)
- 7.3 Global Recombinant Human Interleukin 2 Injection Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Recombinant Human Interleukin 2 Injection Value Chain Analysis
- 8.1.1 Recombinant Human Interleukin 2 Injection Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Recombinant Human Interleukin 2 Injection Production Mode & Process
- 8.2 Recombinant Human Interleukin 2 Injection Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Recombinant Human Interleukin 2 Injection Distributors
- 8.2.3 Recombinant Human Interleukin 2 Injection Customers
9 Global Recombinant Human Interleukin 2 Injection Analyzing Market Dynamics
- 9.1 Recombinant Human Interleukin 2 Injection Industry Trends
- 9.2 Recombinant Human Interleukin 2 Injection Industry Drivers
- 9.3 Recombinant Human Interleukin 2 Injection Industry Opportunities and Challenges
- 9.4 Recombinant Human Interleukin 2 Injection Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst